Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models
The temporal dynamics of these effects demonstrated greater significance than dose-dependent responses. Both VEGFi and VEGFRi significantly augmented the risk of immune-mediated, blood pressure-related adverse events, with VEGFRi inducing a more rapid and pronounced onset of blood pressure elevation and a higher incidence of immune-related, blood pressure-associated adverse events compared to VEGFi.
Authors
- Yuehui Yin (ORCID: https://orcid.org/0000-0001-9769-435X)
- Peng Luo (ORCID: https://orcid.org/0000-0002-8215-2045)
- Kailai Li (ORCID: https://orcid.org/0000-0002-2368-3217)
- Anqi Lin (ORCID: https://orcid.org/0000-0002-6324-0410)
- Jian Zhang (ORCID: https://orcid.org/0000-0002-6558-791X)
- Qingkai Yan
- Hongyu Kuang (ORCID: https://orcid.org/0000-0003-1682-7013)
- Zhanzhi Li
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Zhujiang Hospital (CN)
- Hangzhou Medical College (CN)
- Southern Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-10-22
- DOI
- https://doi.org/10.3389/fimmu.2024.1488853
- Citations
- 11
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 3.93